Abstract
Purpose: To compare patients ≥60 years and ≤40 years old undergoing contemporary hip arthroscopy for femoroacetabular impingement syndrome managed with labral repair and capsular closure using a propensity score‐matched cohort design controlling for sex, body mass index, and Tönnis grade. Methods: A single‐center retrospective review identified patients ≥60 years undergoing primary hip arthroscopy for femoroacetabular impingement syndrome (January 2015‐May 2024) with a minimum 12‐month follow‐up. Exclusion criteria included prior ipsilateral surgery, non‐femoroacetabular impingement syndrome pathology, Tönnis grade ≥2, concomitant procedures, osteotomy, Ehlers‐Danlos syndrome, and isolated labral debridement. Patients were matched 1:2 by sex, body mass index, and Tönnis grade to those aged 18 to 40 years. Patient‐reported outcomes included pre‐ and postoperative Hip Outcome Score‐Activities of Daily Living (HOS‐ADL), Hip Outcome Score Sports‐Specific subscale, and 12‐Item International Hip Outcome Tool. Cohort‐specific minimal clinically important difference, patient acceptable symptom state (PASS), and reoperation‐free survivorship were assessed. Results: Forty‐eight patients (48 hips) ≥60 years (63.7 ± 3.6 years; follow‐up 27.1 [12.0‐72.0] months) were matched to 91 patients (95 hips) 18 to 40 years (31.6 ± 3.5 years; follow‐up 27.5 [12.0‐65.2] months). Both groups improved across all patient‐reported outcomes ( P < .001). Hip Outcome Score Sports‐Specific subscale and 12‐Item International Hip Outcome Tool were comparable pre‐ and postoperatively ( P > .05). The ≥60 cohort had lower HOS‐ADL at baseline (53.0 ± 21.3 vs 63.8 ± 18.2, P = .006) and postoperatively (76.8 ± 23.2 vs 87.3 ± 14.5, P = .002). Minimal clinically important difference achievement and score improvements were similar ( P > .05), as were PASS rates for Hip Outcome Score Sports‐Specific subscale and 12‐Item International Hip Outcome Tool. HOS‐ADL PASS was lower in the ≥60 cohort (47.6% vs 71.6%, P = .015). Survivorship was 93.8% in the ≥60 cohort versus 100% in controls, with reoperations occurring in patients with baseline Tönnis grade 1, bipolar cartilage lesions, and grade ≥2 cartilage lesions. Conclusions: Patients ≥60 years achieved comparable improvement and minimal clinically important difference rates but lower absolute function and HOS‐ADL PASS rates. Survivorship was 94% at 27 months (minimum 12), with failure driven by cartilage damage. Meaningful improvement is achievable in appropriately selected older patients, although expectations and outcome thresholds may differ by age. Level of Evidence: Level III, retrospective comparative cohort study.

This publication has 52 references indexed in Scilit: